WFSBP

The World Federation of Societies of Biological Psychiatry is a non-profit organization composed of National Societies of #BiologicalPsychiatry.
#WFSBP2026

[WFSBP @wfsbp]

From addiction medicine to brain development, Vivek Benegal's research explores vulnerability and resilience to mental illness.
At the WCBP & GCBP Joint Meeting 26 he will present findings from two of India's largest developmental mental health cohorts.
🔗https://t.co/PVKCEEKGHa

[WFSBP @wfsbp]

#EarlyCareer #Workshops at the WCBP & GCBP Joint Meeting 2026 will focus on #AcademicSkills and #Neurosciences. Featuring:
“How to Fail at Lectures, Grants and Papers (or Not)”
and
“Neuroscience for Psychiatrists: Foundations and Clinical Applications”
🔗 https://t.co/AlIsC0WJnb

[WFSBP @wfsbp]

With more than 1650 publications and a focus on novel therapies, Michael Berk has helped shape modern psychiatry research.

At the WCBP & GCBP Joint Meeting 2026, he will be joining: “How to Fail at Lectures, Grants and Papers (or Not)”

🔗 https://t.co/PVKCEELewI

[WFSBP @wfsbp]

From dopamine receptor mapping to bipolar depression research, Jee Hyun Kim connects neuroscience and translational psychiatry.
At WCBP & GCBP Joint Meeting 2026, she joins the Early Career workshop “How to Fail at Lectures, Grants and Papers (or Not)”.
🔗 https://t.co/PVKCEEKGHa

[WFSBP @wfsbp]

How early can Alzheimer’s disease be detected — and what role do biomarkers play in diagnosis and treatment?

At the WCBP & GCBP Joint Meeting 2026, Pedro Rosa-Neto will present: “Development and application of biomarkers for Alzheimer’s disease”

🔗 https://t.co/PVKCEEKGHa

[WFSBP @wfsbp]

Low-dose ketamine and other medication strategies for difficult-to-treat depression in young people remain important topics in psychiatry.

At the WCBP & GCBP Joint Meeting 2026, Christopher Davey discusses evidence gaps in youth #depression treatment.

🔗https://t.co/PVKCEEKGHa

[WFSBP @wfsbp]

Do you have any current findings you would like to present at the WCBP & GCBP Joint Meeting 2026?

The extended late-breaking submission period is open for poster and free communication presentations only.

🗓️ Deadline: 3 June 2026
🔗 https://t.co/InHQIfm41k

[WFSBP @wfsbp]

Collaborative learning networks are becoming increasingly important in bipolar disorder care.

At the WCBP & GCBP Joint Meeting 2026, Andrew A. Nierenberg is presenting: “The Bipolar Action Network: A Collaborative Organization to Improve Outcomes”

🔗 https://t.co/PVKCEEKGHa

[WFSBP @wfsbp]

Haven’t secured your ticket for the WCBP & GCBP Joint Meeting 2026 yet?

Join us in Jaipur, India, 27–30 August 2026, for the latest advances in biological psychiatry.

Regular registration fees available until 31 May 2026.
https://t.co/U6uHOPaXxs

[WFSBP @wfsbp]

⏰ The clock is ticking: #WFSBP2026 Award nominations and applications close on 8 May 2026.
Open across all award categories, recognising contributions in biological psychiatry at every career stage.
🔗 https://t.co/2UZjDTzmSg

[WFSBP @wfsbp]

⏰ Final call: #WFSBP2026 Award nominations and applications close on 27 April 2026.
Recognise outstanding work in biological psychiatry—from early-career researchers to established leaders—across all award categories.
🔗 https://t.co/2UZjDTzmSg

[WFSBP @wfsbp]

Late-breaking abstract submission for #WFSBP2026 is now open.
Share your latest research with an international audience—submissions welcome for free communication and poster presentations.
🗓️Deadline: 3 June 2026
🔗 https://t.co/InHQIfmBQS

[WFSBP @wfsbp]

Know someone whose work deserves recognition?
The deadline for all #WFSBP2026 Award nominations and applications has been extended to 27 April 2026—across all categories, including the Young Investigator Awards.
Nominate outstanding contributions.
🔗 https://t.co/2UZjDTzmSg

[WFSBP @wfsbp]

Gin Singh Malhi (University of Sydney) joins the #WFSBP2026 debate on “Immuno-metabolic depression” as an opponent—raising key questions about evidence and clinical application.
🔗 https://t.co/PVKCEEKGHa

[WFSBP @wfsbp]

Is it time to rethink how we treat depression?
Jane A. Foster joins the “Immuno-metabolic depression” debate as a proponent at #WFSBP2026, exploring how immune and metabolic pathways shape mental health.
🔗 https://t.co/PVKCEELewI

[WFSBP @wfsbp]

Pablo Lapuerta, Founder and CEO of 4M Therapeutics, brings extensive experience in drug development to #WFSBP2026. As part of the Drug Pipeline Symposium, he will share perspectives on novel small molecules for bipolar disorder. 👉https://t.co/PVKCEELewI
#BiologicalPsychiatry

[WFSBP @wfsbp]

Bringing new treatments to patients remains a key challenge in #psychiatry—one that Ravi Anand has worked on throughout his career and will bring to #WFSBP2026. His work focuses on drug development, including glutamate modulators in #schizophrenia. 👉 https://t.co/PVKCEELewI

[WFSBP @wfsbp]

Understanding how antidepressants work remains key to improving treatment. Catherine Harmer’s research shows early effects on emotional processing before mood changes. At #WFSBP2026, her talk explores what this means for more targeted treatments.
👉 https://t.co/PVKCEELewI

[WFSBP @wfsbp]

🏆 Reminder: Applications closing soon
The #WFSBP2026 Young Investigator Awards are open, recognising outstanding early-career researchers in biological psychiatry and related fields.
🗓️ Apply by 13 April 2026
🔗 https://t.co/B65J7VfIVN
#YoungInvestigatorAwards #WFSBP

[WFSBP @wfsbp]

In her work, Cynthia Fu focuses on #neuroimaging biomarkers & neuromodulation to improve classification and predict response in depression. At #WFSBP2026 she will present “Brain Dimensions of #Depression: From #Biomarkers to Home-Based #Neuromodulation.” 👉https://t.co/PVKCEEKGHa